[Phase II clinical study of 99mTc-MAG3].
Phase II clinical study of mercaptoacetylglycyl-glycylglycinate (99mTc) technetium (99mTc-MAG3), a new scintigraphic and renographic agent, was performed to evaluate its safety, clinical usefulness and optimal dosage at 5 institutions in total 88 patients with mild renal or urinary disorders. There was no case showed adverse reaction in patients studied and the administration of the agent was proved to be safe. The effectiveness of the agent was evaluated and revealed to be effective in all cases analyzed. A range of dosage 200-400 MBq was found to be optimal, from image quality and clinical information obtained. It is concluded that 99mTc-MAG3 is a safe and useful radiopharmaceutical for the diagnosis of renal dynamic function.
Ishii
K
K
Department of Radiology, Kitasato University, School of Medicine.
Ishibashi
A
A
Tsukamoto
E
E
Itoh
K
K
Yamamoto
K
K
Ishii
Y
Y
Kobayashi
S
S
Takeda
K
K
Nakagawa
T
T
Hioki
T
T
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging* / Q000503:physiopathology; D007674:Kidney Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011866:Radioisotope Renography; D012079:Renal Circulation; D017263:Technetium Tc 99m Mertiatide / Q000008:administration & dosage; D014570:Urologic Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology
D017263:Technetium Tc 99m Mertiatide